Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 305

Similar articles for PubMed (Select 16096413)

1.
2.

Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.

Shah SS, Wang Y, Tull J, Zhang S.

Diagn Mol Pathol. 2009 Mar;18(1):30-3. doi: 10.1097/PDM.0b013e31817c1af8.

PMID:
19214111
3.

HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.

McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J.

Am J Clin Pathol. 2002 Jun;117(6):935-43.

4.

[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].

Zeng X, Liang ZY, Wu SF, Zhou WX, Gao J, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Chinese.

PMID:
17134563
5.

Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.

Moelans CB, de Weger RA, van Diest PJ.

Breast Cancer Res Treat. 2010 Feb;120(1):1-7. doi: 10.1007/s10549-009-0539-2. Epub 2009 Sep 18.

PMID:
19760503
6.

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM.

J Clin Oncol. 2011 Nov 1;29(31):4168-74. doi: 10.1200/JCO.2011.36.0107. Epub 2011 Sep 26.

7.
8.

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, Piccart M, Larsimont D.

Mol Cancer Ther. 2006 Oct;5(10):2572-9.

9.

[HER2 status in breast cancer of Chinese women: a study of 1170 cases using fluorescence in-situ hybridization].

Zeng X, Liang ZY, Wu SF, Gao J, Zhou WX, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2008 Sep;37(9):594-8. Chinese.

PMID:
19094582
10.

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.

Marchiò C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A.

J Pathol. 2009 Sep;219(1):16-24. doi: 10.1002/path.2574.

PMID:
19670217
11.

Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.

Schlüter B, Gerhards R, Strumberg D, Voigtmann R.

J Cancer Res Clin Oncol. 2010 Sep;136(9):1389-400. doi: 10.1007/s00432-010-0790-2. Epub 2010 Mar 9.

PMID:
20217132
12.

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.

Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T.

BMC Cancer. 2008 Dec 6;8:363. doi: 10.1186/1471-2407-8-363.

13.

HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.

Panvichian R, Tantiwetrueangdet A, Wongwaisayawan S, Nampoon A, Lertsithichai P, Leelaudomlipi S.

Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):367-74. doi: 10.1097/PAI.0b013e31823fc207.

PMID:
22417858
14.

Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.

Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L.

Int J Surg Pathol. 2009 Jun;17(3):198-205. doi: 10.1177/1066896909333415.

PMID:
19443884
15.
16.

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event.

Yeh IT, Martin MA, Robetorye RS, Bolla AR, McCaskill C, Shah RK, Gorre ME, Mohammed MS, Gunn SR.

Mod Pathol. 2009 Sep;22(9):1169-75. doi: 10.1038/modpathol.2009.78. Epub 2009 May 15.

17.

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.

Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F.

Breast Cancer Res. 2005;7(2):R267-73. Epub 2005 Jan 26.

18.

Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.

Kounelis S, Kapranos N, Malamos N, Kouri-Bairaktari E.

Anticancer Res. 2005 Mar-Apr;25(2A):939-46.

19.

[Evaluation of HER2 gene expression status in breast cancer by fluorescence in-situ hybridization].

Zeng X, Zhao DC, Zhou WX, Wu SF, Liang ZY, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):701-5. Chinese.

PMID:
16536311
20.

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.

Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z.

Cancer. 2011 Jan 1;117(1):48-53. doi: 10.1002/cncr.25580. Epub 2010 Aug 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk